CCL5 and melanoma: For melanoma patients treated with OH2 monotherapy, CCL5 levels remained unchanged or decreased in patients with stable disease (SD) and progressive disease (PD) (Figure 9A), while CCL5 levels elevated in patients having partial response (PR) (Figure 9B).